Susquehanna International Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Susquehanna International Group’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-35,475	Closed	-$103K	–	14370
2021 Q3	$103K	Sell	35,475 -43,359	-55%	-$144K	﹤0.01%	12059
2021 Q2	$275K	Buy	78,834 +3,387	+4%	+$11.6K	﹤0.01%	10968
2021 Q1	$258K	Buy	75,447 +19,209	+34%	+$363K	﹤0.01%	10930
2020 Q4	$1.08M	Buy	56,238 +32,584	+138%	+$503K	﹤0.01%	6540
2020 Q3	$318K	Buy	+23,654	New	+$670K	﹤0.01%	8584
2020 Q2	–	Sell	-9,211	Closed	-$298K	–	11293
2020 Q1	$254K	Buy	+9,211	New	+$269K	﹤0.01%	8291

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Susquehanna International Group's ODT Position: Q4 2021 in Review

Susquehanna International Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 35,475 shares — an estimated $103K sold.

Susquehanna International Group first reported a position in ODT in Q1 2020 and held it in 6 quarters. The position peaked at $1.08M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

Susquehanna International Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Susquehanna International Group sold 35,475 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $103K.
Susquehanna International Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
Susquehanna International Group's Odonate Therapeutics, Inc. Common Stock position peaked at $1.08M in Q4 2020.
50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.